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There are few substantive methods to measure the
health of the immune system, and the connection
between immune strength and the viral component
of themicrobiome is poorly understood. Organ trans-
plant recipients are treated with posttransplant
therapies that combine immunosuppressive and
antiviral drugs, offering a window into the effects
of immune modulation on the virome. We used
sequencing of cell-free DNA in plasma to investigate
drug-virome interactions in a cohort of organ trans-
plant recipients (656 samples, 96 patients) and find
that antivirals and immunosuppressants strongly
affect the structure of the virome in plasma. We
observe marked virome compositional dynamics at
the onset of the therapy and find that the total viral
load increases with immunosuppression, whereas
the bacterial component of the microbiome remains
largely unaffected. The data provide insight into the
relationship between the human virome, the state
of the immune system, and the effects of pharmaco-
logical treatment and offer a potential application of
the virome state to predict immunocompetence.
INTRODUCTION
The human microbiome is now recognized as an important
component of human health (Turnbaugh et al., 2007). Commu-
nity-level analyses have shed light on factors that shape the
structure of the bacterial component of the microbiome, such
as age (Yatsunenko et al., 2012), diet (De Filippo et al., 2010;
Muegge et al., 2011), geographical location (Yatsunenko et al.,
2012), antibiotic treatment (Jakobsson et al., 2010), and disease
(Clemente et al., 2012). The viral component of the microbiome,
the human virome, remains relatively understudied (Wylie et al.,
2012) and little is known about the effects of immunemodulation1178 Cell 155, 1178–1187, November 21, 2013 ª2013 Elsevier Inc.and antiviral therapies on virome composition. It was previously
shown that the healthy gut virome remains remarkably stable
over time (Reyes et al., 2010), and that the predominant source
of variation is due to differences between subjects, although
an association between diet and the virome composition was
found (Minot et al., 2011). Here, we study the dynamic response
of the human virome in plasma to antiviral drugs and strong
perturbations of the immune system as experienced by organ
transplant recipients.
Immunosuppressive therapies significantly reduce the risk of
graft rejection in organ transplantation but increase the suscep-
tibility of recipients to infections (Fishman, 2007). Infections with
viral pathogens, in particular the herpesvirus cytomegalovirus
(CMV), occur frequently and increase the recipient’s risk of graft
failure (Fishman et al., 2007). Organ transplant recipients are
therefore frequently subjected to antiviral prophylactic or pre-
emptive therapies directed against CMV (Slifkin et al., 2004).
The inverse relationship between the level of immunosuppres-
sion and the risks of infection and rejection leaves only a narrow
therapeutic window available for patient treatment (see Fig-
ure 1A). Posttransplant care is further complicated by numerous
limitations of the currently available methods for the diagnosis of
infection and rejection. Diagnosis of rejection mostly relies on
invasive biopsies that suffer from interobserver variability, high
cost, and patient discomfort (Marboe et al., 2005; Saraiva
et al., 2011; Snyder et al., 2011). Diagnosis of infections is chal-
lenging given the fact that the symptoms of infection are dimin-
ished following immunosuppression (Fishman, 2007) and
commonly used diagnostic methods, such as antigen-detection
and PCR-based molecular tests, rely on a specific target and
therefore an a priori hypothesis for the source of the infection.
As a final complication, patient-to-patient variability in the sensi-
tivity to immunosuppressive drugs can give rise to over- and
underimmunosuppression, increasing the risk of infection or
rejection, respectively (Budde et al., 2011; Wieland et al., 2010).
In this work, we sequenced cell-free DNA circulating in plasma
to investigate drug-microbiome interactions following organ
transplantation. We studied the patterns of infection in heart
and lung transplant recipients subjected to a combination of
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Figure 1. Study Design, Read Statistics, and Phylogenetic Distribution
(A) Immunosuppression reduces the risk of rejection in transplantation but increases the risk of infection.
(B) Design of study: 656 plasma samples were collected, cell-free DNA was purified and sequenced to an average depth of 1.25 Gbp per sample.
(C) Number of samples collected as function of time for the different patient groups part of the study.
(D) Treatment protocol for patients in the study cohort, all patients are treated with maintenance immunosuppression (tacrolimus-based [TAC] for adult heart and
lung transplant recipients and cyclosporine [CYC] for pediatric patients). CMV positive (donor or recipient, CMV+) transplant cases are treated with anti-CMV
prophylaxis, valganciclovir (VAL). Mean level of tacrolimusmeasured in blood of transplant recipients treated with a TAC-based protocol (dashed line actual, solid
line window average filter).
(E) Fraction of reads that remain after filtering of lower quality and duplicate reads (mean 86%, left) and after removal of human and low-complexity reads (mean
2%, right).
(F) Relative genomic abundance at different levels of taxonomic classification after removal of human reads (average over all samples from all organ transplant
recipients [n = 656]). The central pie chart shows the composition at the superkingdom level of classification. Lower levels of classification are shown in donut
charts with progressively larger radius.
See also Figure S1.
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immunosuppressants and antiviral prophylaxis. We find that
immunosuppressants and antivirals have a strong influence on
the structure of the viral component of the microbiome but not
the bacterial component. Strong compositional dynamics are
observed at the onset of the drug therapy as the virome compo-
sition of different individuals converge to a similar, drug-deter-
mined state. The total viral load increases markedly in response
to the therapy, as viruses, in particular the anelloviruses, take
advantage of a reduction of immunocompetence. Finally, we
show that measurement of the anellovirus burden enables strat-
ification of rejecting and nonrejecting recipients.
RESULTS
A total of 656 plasma samples were collected longitudinally from
96 solid-organ transplant recipients (41 adult heart, 24 pediatric
heart, 31 adult lung). Cell-free DNA was purified from plasma
(Fan et al., 2008) and sequenced. In total, we obtained 820
Gbp of sequencing data, with an average of 1.25Gbp per sample
(Illumina HiSeq, 13 50 bp reads, Figure 1B). Organ transplant re-
cipients were continuously enrolled in the study over the course
of more than 2 years and samples were collected from the recip-
ients at regular time points posttransplant, with the highest fre-
quency of sample collection in the first months posttransplant
(see Supplemental Information). Figure 1C shows the number
of samples analyzed as a function of time posttransplant for
the different patient classes.
The patients in the cohort were treated with antiviral prophy-
laxis and immunosuppression as part of a standardized post-
transplant therapy (Figure 1D, for more details of the protocol,
see Supplemental Information). Maintenance immunosuppres-
sionwas tacrolimus-based for the adult heart and lung transplant
recipients and was complemented with mycophenolate mofetil
and prednisone. Pediatric patients were treated with a cyclo-
sporine-based antirejection therapy. CMV positive transplant re-
cipients (prior CMV infection for recipient and/or donor), but not
CMV negative recipients, were treated with antiviral prophylaxis.
The protocol design entails high doses of immunosuppressants
and antiviral drugs in the first few months posttransplant, after
which the doses are gradually reduced as the risks of rejection
and infection diminish. Given the narrow therapeutic window
available for immunosuppression and the large patient-to-
patient variability in pharmacokinetics of tacrolimus (Jusko
et al., 1995; Venkataramanan et al., 1995), the concentration of
tacrolimus is directly measured in the blood and the dose is
adjusted to maintain a target drug level (see Supplemental
Information for details). Figure 1D shows the mean level of tacro-
limus measured in blood for the tacrolimus-treated patients and
illustrates the design of the drug treatment protocol.
DNA Sequence Analysis
Microbiome-derived sequences were identified after computa-
tional subtraction of human-derived sequences (Weber et al.,
2002; Xu et al., 2003). To this end, duplicate and low-quality
reads were removed and the remaining reads were mapped
to the human reference genome, build hg19 (BWA [Li and Dur-
bin, 2009], see Experimental Procedures). Unmapped reads
were then collected, and low-complexity reads were removed1180 Cell 155, 1178–1187, November 21, 2013 ª2013 Elsevier Inc.(SEQCLEAN, http://compbio.dfci.harvard.edu/tgi/software/).
Figure 1E shows the distribution of the remaining read fraction
after applying duplicate and quality filters (average of 86%)
and the distribution of the remaining fraction after subtraction
of human reads (average of 2%).
To identify infectious agents, the remaining, high quality,
unique, nonhuman reads were mapped using BLAST to a refer-
ence database of viral (n = 1,401), bacterial (n = 1,980) and fungal
(n = 32) genomes (downloaded from NCBI ftp://ftp.ncbi.nih.gov/
genomes on June 14, 2012, see Extended Experimental Proce-
dures and Figure S1A available online). 0.12% of the uniquely
sequenced reads aligned to at least one of the target genomes
(Figures S1B and S1C). We used a quantitative PCR (qPCR)
assay targeted to a subset of sequencing identified targets
(herpesviruses 4,5,6 and parvovirus) to validate the positive
hits identified by the sequencing-based approach. We found a
quantitative agreement between viral counts as measured by
sequencing and qPCR (Figure S1D). We furthermore found that
the sensitivity of the sequencing assay for the detection of
herpesviruses is on par with qPCR measurements. The larger
capture cross-section available to the sequencing assay—the
complete target genome versus the PCR amplicon target re-
gion—is thus sufficient to overcome the signal loss in sequencing
caused by the finite efficiency of sequencing library preparation
and library undersampling. The highest CMV loads measured
using sequencing across all samples in the study corresponded
to twoadult heart transplant patients that suffered fromaclinically
diagnosed disseminated CMV infection (see Figure S1E).
To test for the presence of potential contaminants in the
reagents used for DNA extraction and sequencing library prepa-
ration, we performed two control experiments. In the first, we
prepared two samples consisting of a defined template (Lambda
gDNA, Pacbio Part no. 001-119-535) and purified DNA for
sequencing using the above-described workflow (Illumina
Miseq, 3.4 and 3.5 million reads). Lambda-derived sequences
were removed and the remaining sequences (0.4%)were aligned
to the BLAST reference database described above. No evidence
was found for the various infectious agents discussed in this
work, but we did detect sequences related to the Enterobacter-
iaceae bacterial family (phylum Proteobacteria), primarily E. coli
(>97%), and enterobacterial phages (<1%), which are likely a
remnant of the lambda DNA culture. In a second control, we
prepared a sample for sequencing from nuclease-free water.
The sample was included in a sequencing run along with a sam-
ple unrelated to this study and recruited only a limited number of
sequences, 15 in total, which mapped to genomes of two bacte-
rial species (see Supplemental Information). Again, no evidence
was found for the infectious agents that are discussed below.
We studied the microbiome composition in plasma at different
levels of taxonomic classification using GRAMMy (Xia et al.,
2011), a tool that utilizes the sequence-similarity data obtained
with BLAST to perform a maximum likelihood estimation of the
relative abundance of species. GRAMMy accounts for differ-
ences in target genome size and the ambiguity of read assign-
ments. This approach only allows estimating the abundance of
species for which genomic data are available in the reference
database. Figure 1F shows the relative abundance of species
at different levels of taxonomic classification (average over all
samples). We find that viruses (73%) are more abundantly repre-
sented than bacteria (25%) and fungi (2%) (Figure 1F, a). Among
viruses, we find that ssDNA viruses occupy a larger fraction
(72%) than dsDNA viruses (28%). Seven distinct viral families
are found (abundance > 0.75%), with one dominant family, the
Anelloviridae, which accounted for 68% of the total population
(Figure 1F, b). The anelloviridae fraction is mostly (97%)
composedof viruses from theAlphatorquevirus genus (Figure 1F,
c). The Alphatorque genus is the genus of Torque Teno Viruses
(TTVs), and sequences related to 14 different torque teno viro-
types were identified (Figure 1, d). Infections with polyomavi-
ruses are widespread in the human population (Chesters et al.,
1983), and polyomavirus DNAemia is not uncommon in the first
year after solid-organ transplantation (Razonable et al., 2005).
Polyomavirus-derived sequences were found in 75 samples
(11%) corresponding to 36 patients in the present cohort. Evi-
dence for the presence of BK (41%), JC (27%), TS (4%), WU
polyomavirus (6%), SV40 (6%), and the recently discovered
HPyV6 (13%) (Schowalter et al., 2010) was found (Figure 1F,
e). Among bacteria, Proteobacteria (36%), Firmicutes (50%),
Actinobacteria (10%), and Bacteroidetes (4%) are the phyla
most abundantly represented in the sample (Figure 1F, f).
To investigate potential incorrect assignments of the relatively
short reads available to this study (50 bp), we examined the
dependence of the abundance estimates on read length, based
on longer, paired-end reads (2 3 100 bp) collected for a subset
of samples (n = 55). We found that the abundance estimates
based on 50 bp subreads and 100 bp reads are similar for all
levels of taxonomic classification reported here (Figure S1F).
Sensitivity of Virome Composition to Drug Dosage
The available clinical data on drug dosage was used to analyze
drug-microbiome interactions. Here, we examined data for the
adult heart and lung transplant patients that were treated with
a tacrolimus-based antirejection protocol (47 patients and 380
observations), thereby excluding the pediatric patients that
were treated with cyclosporine and patients that were switched
from tacrolimus to cyclosporine immunosuppression due to
drug-intolerance issues. Data on prescription antiviral drug
doses (valganciclovir) and the measured levels of tacrolimus in
blood were collected from individual patient records and the
mean composition for samples corresponding to different drugs
levels was extracted. To account for the delayed effect of micro-
biome composition on dose changes, the drug level and dose
data were sliding-window average filtered (see Figures 1D and
S2A–S2C; window size 45 days).
We found that the structure of the viral component of the
microbiome is a sensitive function of drug dosage (47 patients,
380 samples, Figure 2A). However, the structure of the bacterial
component of the microbiome was not significantly altered by
the drug therapy, as discussed further below (Figure S2D).
Herpesvirales and caudovirales dominated the virome when
patients received a low dose of valganciclovir and tacrolimus.
In contrast, a high dose of immunosuppressants and antivirals
gave rise to a virome structure that is dominated by anelloviridae
(up to 94% occupation at high drug levels). The antiviral prophy-
laxis is intended to prevent CMV disease, but other herpesvi-
ruses are also susceptible to the drug (Razonable, 2011) so itCis not surprising that a higher dose of valganciclovir gives rise
to a lower fraction of viruses from the Herpesvirales order. The
observation that anelloviridae take advantage of suppression
of the host immune system is consistent with various observa-
tions from the literature: it was previously shown that the inci-
dence of anelloviridae increases with progression toward AIDS
in HIV patients (Madsen et al., 2002; Thom and Petrik, 2007)
and that the total burden of the anellovirus TTV increases post-
liver transplantation (Thom and Petrik, 2007). Furthermore, an
increased prevalence of anelloviridae in pediatric patients with
fevers was reported recently (McElvania TeKippe et al., 2012).
We next compared the virome composition measured for
organ transplant recipients to the composition observed in
healthy individuals, not on immunosupressants or antivirals
(n = 9, sequencing data available from a previous study). Here,
we compare the healthy composition to the composition
measured for organ transplant recipients at the start of the
drug therapy (postoperative day 1, n = 13), corresponding to a
minimal drug exposure, and to the composition measured for
transplant recipients exposed to high drug levels (well
after the transplant procedure, tacrolimus R 9 ng/ml.
valgancicolvirR 600 mg, n = 68). We find a similar composition
of the virome for the healthy reference samples and samples cor-
responding to minimal drug exposure (Figure 2B). However, the
compositions of the healthy reference and minimal drug expo-
sure samples are distinct from the anelloviridae-dominated
composition measured for high drug-exposure samples.
The tacrolimus-based immunosuppressive therapy is comple-
mented with induction therapy in the first 3 days posttransplant
(with antithymocyte globulin, daclizumab, or basiliximab) and
the patients furthermore receive the corticosteroid prednisone
throughout the posttransplant therapy (see Supplemental Infor-
mation). The time-dosage profile for prednisone and tacrolimus
are similar: high doses at the onset of the therapy followed by
a gradual dose reduction (Figures S2A–S2C). The data in
Figure 2A thus reflect the combined effect of prednisone and
tacrolimus. An analysis of the differential effect of prednisone
and valganciclovir on the virome composition (Figure S2E)
shows the same trend observed in Figure 2A: higher prednisone
doses lead to a larger representation of anelloviruses. Lastly, we
note that a subset of patients was not treatedwith antiviral drugs.
The data corresponding to this subset of patients allowed us to
further disentangle the differential effect of the antiviral drugs
and the immunosuppressants on the composition of the virome,
as described below.
Partitioning of Microbiome Diversity
We studied the diversity of the bacterial and viral components of
the microbiome and found that the within-subject diversity was
lower than the between-subject diversity, both for bacteria and
viruses (Bray-Curtis beta diversity, bacterial composition at
phylum level, viral composition at family and order level, Fig-
ure 2C) (Oksanen et al., 2007). Partitioning the data for patients
according to transplant type (heart or lung) did not reduce the
diversity for bacteria and viruses (decrease in mean diversity <
0.001 for viruses, 95% confidence, Welch two-sample t test).
Partitioning samples according to the age of the patient at time
of transplant had a minor effect on sample-to-sample diversityell 155, 1178–1187, November 21, 2013 ª2013 Elsevier Inc. 1181
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Figure 2. Relative Viral Genomic Abundance as a Function of Drug Dose and Comparison to Healthy Reference
(A) Mean virome composition for patients treated with the immunosuppressant tacrolimus (47 patients, 380 samples) as function of antiviral drug dose (val-
ganciclovir) and concentration tacrolimus measured in blood. To account for the delayed effect of the virome composition on drug dose, the data on drug doses
were window average filtered (window size 45 days, see Figure 1C). Herpesvirales and caudovirales dominate the virome when patients receive low doses of
immunosuppressants and antiviral drugs. Conversely, anelloviridae dominate the virome when patients receive high doses of these drugs.
(B) Comparison of virome composition corresponding to healthy references (n = 9), posttransplant day 1 samples with low drug exposure, (n = 13), and samples
corresponding to high drug exposure (tacrolimusR 9 ng/ml, valganciclovirR 600mg, n = 68). The virome structure for day 1 samples (1) and the virome structure
measured for a set of healthy individuals (H) are distinct from the anellovirus-dominated distribution measured for samples corresponding to high drug doses (D).
The pie charts show the mean fractions, p values in box plot based on the Mann-Whitney U test.
(C) Bray-Curtis beta diversity for all samples, among patients with the same transplant type (heart or lung), same age at time of transplant (10 year bins), within
subjects, for patients treated with a similar drug dosage (tacrolimus level ± 0.5 ng/ml, valganciclovir ± 50 mg), and for samples collected from the same subjects
within a 1 month time span.
See also Figure S2.(10 year bins, decrease in mean diversity < 0.035 for viruses,
95% confidence, Welch two-sample t test). Within subjects,
the diversity was lower for samples collected within a one month
time span, again both for bacteria and viruses. For viruses but
not for bacteria, we find that the diversity is lower when
comparing samples collected at a similar drug dosage (tacroli-
mus level ± 0.5 ng/ml, valganciclovir ± 50 mg). Taken together
with the sensitivity of the population averages to drug dosage1182 Cell 155, 1178–1187, November 21, 2013 ª2013 Elsevier Inc.in Figure 2A, we thus find that the composition of the virome
for patients that are subject to the same drug therapy converges
to a similar state.
Dynamic Response of Virome to Drug Dose Changes
A strong temporal response of the virome to changes in drug
dosage is observed, consistent with the sensitivity of the virome
composition to drug dosage. Figure 3A shows the time
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C D
Figure 3. Temporal Dynamics of the Micro-
biome Composition Posttransplant
(A) Relative abundance of dsDNA and ssDNA
viruses for different time periods (average for
all samples). The relative abundance of ssDNA
viruses increases rapidly after the onset of the
posttransplant drug therapy. After 6 months, the
opposite trend is observed.
(B) Viral genome abundance at the family and
order level of taxonomic classification for different
time periods. The fraction of anelloviridae expands
rapidly in the first several months posttransplant.
The fraction of herpesvirales, caudovirales, and
adenoviridae decreases in that same time period.
After 6 months, the opposite trends are observed.
(C) Time-variation in the relative abundance of
bacterial phyla. Compared to the viral abundance,
the representation of different bacterial phyla
remains relatively unchanged over the observed
posttransplant period.
(D) Shannon entropy as a measure of the within-
sample alpha-diversity for bacterial and viral
genera as function of time (data grouped per
1 month time periods).
See also Figure S3.dependence of the relative genomic abundance of ssDNA and
dsDNA viruses (data from all patient groups and samples, n =
656). The fraction of ssDNA viruses expands rapidly during the
first months posttransplant followed by the opposite trend after
6 months. Figure 3B shows the time-dependent relative compo-
sition of the most abundant viruses grouped at the family and
order level and providesmore detail on the virome compositional
dynamics (data from all patient groups and samples, n = 656).
The dsDNA fraction consists of caudovirales, adenoviridae, pol-
yomaviridae, and herpesvirales, which together occupy 95% of
the virome in the first week posttransplant. ssDNA viruses
only occupy 5% of the initial virome and mainly consist of mem-
bers of the anelloviridae family. The fraction occupied by adeno-
viridae, caudovirales and herpesvirales decreases strongly in
the first few months as these virotypes are effectively targeted
by the antiviral prophylaxis. In contrast, the relative abundance
of anelloviridae increases rapidly as these virotypes largely
escape targeting by the antiviral drugs and take advantage of
the reduced immunocompetence of the patients (maximum of
84%duringmonths 4.5–6). Six months after the organ transplant
procedure, the opposite trends are observed, consistent with the
reduction in antiviral and immunosuppressant drugs prescribed
by the therapeutic protocol.
Compared to the viral component, the bacterial component of
the microbiome remains relatively stable over time, an observa-
tion that is made at the phylum, order, and genus taxonomic
levels (Figure 3C, n = 656, and Figure S3). Figure 3D shows the
within-sample alpha diversity for the bacterial and viral genera
as function of time (Shannon entropy, one month time periods,
590 bacterial genera, 168 viral genera examined). The diversity
of observed viral genera decreases at the onset of the therapy
(1.05 ± 0.5 in month 1 to 0.31 ± 0.33 in months 4–5, p < <
106, Mann-Whitney U test), whereas the alpha diversity of
bacteria remains relatively unchanged during the course of theCposttransplant therapy (2.2 ± 1.14 in month 1 to 2.6 ± 0.85 in
months 4–5, p = 0.1, Mann-Whitney U test).
Increase in Total Viral Load at Onset of Posttransplant
Therapy
To obtain insight into the effect of therapeutic drugs on total viral
load, we extracted the absolute genomic abundance of all
viruses relative to the number of human genome copies by
normalizing the genome coverage of the viral targets to the
coverage of the human genome (see Supplemental Information).
For all patient groups part of this study an increase in total viral
load is observed at the onset of the therapy (Figure 4A), regard-
less of transplant type (heart or lung) or age (adult or pediatric)
(change in load, 7.4 ± 3, sigmoid fit, black line). Combined with
relative abundance data, the total viral load data reveals a net
reduction of the Herpesvirales load and a net increase in anello-
viridae load in the first 3 months posttransplant for patients that
are simultaneously treated with antivirals and immunosuppres-
sants. The data thus show a differential effect of the combination
of antivirals and immunosuppressants on different virotypes. The
data also show a reduction in total adenoviridae load, indicating
that adenoviridae replication is suppressed by valganciclovir, in
agreement with previous studies (Avivi et al., 2004; Bruno et al.,
2003). Figure 4B summarizes data for all transplant types, but
the same trends are observed when stratifying according to
different transplant types: adult heart transplant recipients (n =
268, Figure S4A), adult lung transplant recipients (n = 166, Fig-
ure S4B), and the pediatric patients that are treated with cyclo-
sporine as opposed to tacrolimus (n = 99, Figure S4C).
Not all patients in the study cohort received both antiviral and
immunosuppressant drugs: for transplant cases where both the
donor and recipient do not show evidence of a prior CMV infec-
tion in a CMV antibody assay, it is judged that the risks of com-
plications due to antiviral prophylaxis outweigh the potential riskell 155, 1178–1187, November 21, 2013 ª2013 Elsevier Inc. 1183
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Figure 4. Virome Composition and Total Viral Burden in the Absence and Presence of Antiviral Prophylaxis
(A) Absolute viral load as a function of time, measured as viral genome copies per human genome copies detected by sequencing. Box plots are shown for
different time periods with centers of the time periods marked on the x axis. For all patient classes, the total viral load increases in the first weeks posttransplant
(black line is sigmoid fit, change in load 7.4 ± 3).
(B) Viral load and composition for CMV positive patients (prior CMV infection recipient and/or donor) that are treated with both immunosuppressants and antiviral
drugs (78 patients, 543 samples).
(C) Viral load and composition for CMV negative patients, only treated with immunosuppressants (12 patients, 75 samples).
See also Figure S4.of a newly acquired CMV infection, and the patients are accord-
ingly not treated with antiviral prophylaxis. These patients are
thus solely treated with immunosuppressants. Figure 4C shows
the time dependent viral load and composition of the CMV nega-
tive cases (n = 75). The net effect of immunosuppressant-only
therapy is an expansion of all virotypes, including Herpesvirales
and adenoviridae. Tapering of immunosuppression leads to a
reduction of the total viral load.
Lower Anellovirus Burden in Patients Suffering from a
Graft Rejection Episode
Given the correlation of the anellovirus burden with the extent of
immunosuppression (see Figure 2A and Figure 4), and given the
association between immunocompetence and the risk of rejec-
tion, we asked whether the anellovirus burden can be used for
the classification of rejecting and nonrejecting graft recipients.
Figure 5A shows the anellovirus load measured for rejecting
and nonrejecting patients as function of time posttransplant.
Here, patients are classified as rejecting if they suffer
from at least one biopsy-determined moderate or severe rejec-
tion episode, biopsy grade R 2R/3A (Stewart et al., 2005) (in
red; 20 patients, 177 data points). The rejection-free patients
correspond to patients that are not diagnosed with a
moderate or severe graft damage throughout their posttrans-
plant course (in blue; biopsy grades < 2R/3A, 40 patients, 285
data points). Figure 5A shows that the anellovirus burden is
significantly lower for the rejecting individuals at almost every
time point. We next directly compared the anellovirus burden
for patients at rejection with the burden measured for patients
in the absence of rejection. To account for the time dependence
of the anellovirus load described above (Figure 5A), we extract
the anellovirus load relative to the mean load measured for all
samples at the same time point. Figure 5B shows the time-
normalized load for nonrejecting patients (n = 208) compared
to the load measured for patients suffering from a mild rejection
event (biopsy grade 1R, n = 102) and patients suffering from a se-1184 Cell 155, 1178–1187, November 21, 2013 ª2013 Elsevier Inc.vere rejection episode (biopsy gradeR 2R/3A, n = 22). The figure
shows that the time-normalized loads are significantly lower for
the patients at greater risk of rejection. p values were calculated
by random sampling of the population with a greater amount of
measurement points, p = sum(median(Arej) > median(Anon-rej))/
N, where N = 104 and Arej and Anon-rej are the relative viral loads
for the populations at greater and lesser risk of rejection and
nonrejecting respectively (p = 0.011, p = 0.0002 and p = 0.036).
These observations are in line with a view that the risk of rejec-
tion and the incidence of infection have an opposite association
with the patients’ immunocompetence (see inset Figure 5A). The
lower viral load observed for rejecting patients is thus indicative
of a higher level of immunocompetence in this subgroup of
patients, even though these patients are treated with the same
immunosuppressive protocol. Patient-to-patient variability in
the sensitivity to suppression of immune function is known to
occur (Wieland et al., 2010) and the lack of predictability in immu-
nosuppression is an important risk factor in transplantation. A
commercial assay for the measurement of immunocompetence
is available but was found not to be predictive of acute rejection
or significant infections (Rossano et al., 2009). The development
of methods for the direct measurement of immunocompetence
that can replace or complement existing assays will therefore
be important (Wieland et al., 2010). The total anellovirus load
recorded in organ transplant recipients could serve as an alter-
native marker (Touinssi et al., 2001); Figure 5C shows a
receiver-operating characteristic (Sing et al., 2005) and tests
the performance of the relative anellovirus load in classifying
nonrejecting and rejecting patients (area under the curve = 0.72).
DISCUSSION
We have studied drug-microbiome interactions following solid-
organ transplantation by sequencing cell-free DNA in the recip-
ients’ plasma. The data reveal much about the fundamental
structure of the human virome in plasma and how it responds
AB
C
Figure 5. Lower Anellovirus Burden in
Patients that Suffer from Graft Rejection
(A) Time dependence of the anellovirus load in the
subgroup of patients that suffer from a severe
rejection episode (biopsy grade R 2R/3A, red
data, 20 patients, 177 time points) and in the
subgroup of patients with a rejection-free post-
transplant course (biopsy grades < 2R/3A, blue
data, 40 patients, 285 time points). Box plots are
shown for different time periods with centers of
the time periods marked on the x axis. Solid lines
are cubic splines (smoothing parameter 0.75). The
inset shows a cartoon of the expected inverse
relationship between the level of immuno-
suppression and the incidence of rejection and
infection.
(B) Anellovirus load relative to the average load
measured for all samples at the same time point.
The time-normalized load for nonrejecting patients
(n = 208) is compared to the load measured for
patients suffering from a mild rejection event
(biopsy grade 1R, n = 102) and patients suffering
from a severe rejection episode (biopsy gradeR 2R/3A, n = 22). The p values reflect the probability that themedian viral load is higher for the subgroups at greater
risk of rejection. The p values are calculated by random sampling of the population with a greater amount of measurement points. N-fold random sampling,
p = sum(median(Arej) > median(Anon-rej))/N), where N = 10
4 and Arej and Anon-rej are the relative viral loads for the populations at greater and lesser risk of rejection
and nonrejecting respectively.
(C) Test of the performance of the relative anellovirus load in classifying patients as nonrejecting versus severely rejecting, receiver-operating characteristic curve,
area under the curve = 0.72.to pharmacological perturbation; they also show the relative
insensitivity to immunosuppression of the composition of the
bacterial component of the microbiome. These data may help
in the future design and optimization of posttransplant therapeu-
tic protocols. For example, they show that tapering of antiviral
prophylaxis from initial high doses leads to a resurgence of the
herpesvirales fraction. CMV DNA load has previously been
shown to predict CMV disease relapse and rejection (Potena
et al., 2007; Sia et al., 2000), raising the question of whether
patients would benefit from longer-term prophylactic therapy.
The marked expansion in abundance of anelloviridae upon
immunosuppression is alsoworth further consideration. Anellovi-
ruses are ubiquitous in the human population and, although no
pathogenicity has been established (Hino and Miyata, 2007),
anelloviruses are currently under investigation aspotential cofac-
tors in carcinogenesis (zur Hausen and de Villiers, 2009). The
sensitivity of anelloviridae to immunosuppression makes organ
transplantation an ideal setting for the study of the properties of
anelloviridae, particularly in the light of the increased incidence
of cancer seen in transplant recipients. The observation of a
lower-than-averageburdenof anelloviruses inpatients that suffer
from a rejection episode is indicative of insufficient immunosup-
pression in this subgroup of patients, even though these patients
were subject to the immunosuppressant levels prescribed per
protocol. This suggests that there would be value in designing
assays that allow directly gauging the level of a patient’s immu-
nocompetence, in addition to measurements of circulating drug
levels. The total burden of anelloviruses identified in a transplant
recipient’s blood may serve as one such marker of the overall
state of immunosuppression of the individual patient.
We expect that high-throughput DNA sequencing will find
future applicability in the hypothesis-free diagnosis of infections.CThis approach may be of particular relevance in the context of
transplantation given the fact that infections occur frequently in
transplantation and are difficult to diagnose in immunocom-
promised individuals, and given that sequence analysis can
additionally provide information on the graft health through the
quantification of donor-derived human DNA circulating in
plasma (Snyder et al., 2011). In other areas of infectious
disease, it may be of value to develop subtractive methods to
eliminate the human DNA and enrich for DNA of viral and micro-
bial origin.
EXPERIMENTAL PROCEDURES
Clinical Sample Collection
Patients were enrolled at Stanford University Hospital (SUH) or Lucile Packard
Children’s Hospital (LPCH), and were excluded if they were recipients of multi-
organ transplants. This study was approved by the Stanford University Institu-
tional Review Board (protocol #17666) and enrollment commenced in March
2010. For details on patient recruitment and posttransplant treatment of the
patients see the Extended Experimental Procedures section.
Plasma Processing and DNA Extraction
Plasmawas extracted fromwhole-blood samples within three hours of sample
collection, as previously described (Fan et al., 2008), and stored at 80C.
When required for analysis, plasma samples were thawed and circulating
DNA was immediately extracted from 0.5–1 ml plasma using the QIAamp
Circulating Nucleic Acid Kit (QIAGEN).
Sequencing Library Preparation and Sequencing
Sequencing libraries were prepared from the purifed patient plasma DNA
using the NEBNext DNA Library PrepMaster Mix Set for Illumina with standard
Illumina indexed adapters (purchased from IDT), or using a microfluidics-
based automated library preparation platform (Mondrian SP Ovation SP
Ultralow library system). Libraries were characterized using the Agilent 2100
Bioanalyzer (high-sensitivity DNA kit) and quantified by qPCR. Samples wereell 155, 1178–1187, November 21, 2013 ª2013 Elsevier Inc. 1185
part of 26 different sequencing runs and were sequenced over the course of
22 months. On average, six samples were sequenced per lane.
ACCESSION NUMBERS
The Sequence Read Archive accession number for the sequence data
reported in this paper is SRP032345.
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four figures and can be found with this article online at http://dx.doi.org/10.
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